Remedy for improving ICC prognosis
| Autor: | Tatsuya Tsuji, Shigeharu Takai, Seiki Tashiro, Yuko Sumise, Hitomi Kamo, Hidenori Miyake, Kazuo Yoshioka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Poor prognosis Carcinoma Hepatocellular hepatitis virus lenvatinib General Biochemistry Genetics and Molecular Biology Cholangiocarcinoma hepatocellular carcinoma (HCC) chemistry.chemical_compound Internal medicine medicine Humans In patient Radical surgery Surgical treatment Survival rate Intrahepatic Cholangiocarcinoma nibolumab Hepatitis virus intrahepatic cholangiocarcinoma (ICC) business.industry Liver Neoplasms General Medicine Prognosis Bile Ducts Intrahepatic Bile Duct Neoplasms chemistry Lenvatinib business |
| Zdroj: | The Journal of Medical Investigation. 68:15-21 |
| ISSN: | 1349-6867 1343-1420 |
| Popis: | The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is still poor, and the 5-year survival rate in patients undergoing radical surgery (R0) is less than one-third. Since the prognosis depends mainly on tumor factors, so early diagnosis is necessary. To extend the survival time of these patients with a poor prognosis, cases of long-term survival were examined based on the results of our experiences and the literature. It was found that the hepatitis virus was highly involved in the carcinogenesis of ICC, and patients who were infected with hepatitis virus had rather good survival. J. Med. Invest. 68 : 15-21, February, 2021. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|